A Phase 3 Randomized, Double-blind, Placebo controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Evaluate the efficacy and safety of enzalutamide plus ADT versus placebo plus ADT in subjects with mHSPC
-Subject must be a man age ≥ 18 years of age
-Prior pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer. Exceptions are:
Enzalutamide- Constipation, weight loss decreased appetite, diarrhea, falls, fatigue, swelling of limbs, joint pain, muscle weakness, muscle and bone pain, back pain, headache, anxiety, trouble falling /staying asleep, hematuria, hot flashes, altered taste in mouth, mental impairment, broken bones, spinal cord compression, decreased WBC count, hallucination, dry skin, itching, restless leg syndrome, gynecomastia.
Interested in enrolling in this trial? Please call 717-431-2285.